...
首页> 外文期刊>Journal of Cytology >The Bethesda system for reporting thyroid fine needle aspirates: A cytologic study with histologic follow-up
【24h】

The Bethesda system for reporting thyroid fine needle aspirates: A cytologic study with histologic follow-up

机译:报告甲状腺细针抽吸的Bethesda系统:一项组织学随访的细胞学研究

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background:The Bethesda system for reporting thyroid cytopathology represents a major step towards standardization, reproducibility, improved clinical significance, and greater predictive value of thyroid fine needle aspirates (FNAs).Aims:To elucidate the utility of the Bethesda system in reporting thyroid FNAs.Materials and Methods:We retrospectively reviewed thyroid FNAs between April 2009 and March 2012, classified them using the Bethesda system, found out the distribution of cases in each Bethesda category, and calculated the malignancy risk for each category by follow-up histopathology.Results:Of the 1020 FNAs, 1.2% were non-diagnostic, 87.5% were benign, 1% were atypical follicular lesion of undetermined significance (AFLUS), 4.2% were suspicious for follicular neoplasm (SFN), 1.4% were suspicious for malignancy (SM), and 4.7% malignant. Of 69 cases originally interpreted as non-diagnostic, 12 remained non-diagnostic after re-aspiration. In 323 cases, data of follow-up histopathologic examination (HPE) were available. Rates of malignancy reported on follow-up HPE were non-diagnostic 0%, benign 4.5%, AFLUS 20%, SFN 30.6%, SM 75%, and malignant 97.8%.Conclusions:Reviewing the thyroid FNAs with the Bethesda system allowed a more specific cytological diagnosis. In this study, the distribution of cases in the Bethesda categories differed from some studies, with the number of benign cases being higher and the number of non-diagnostic and AFLUS cases being lower. The malignancy risk for each category correlated well with other studies. The Bethesda system thus allows standardization in reporting, improves perceptions of diagnostic terminology between cytopathologists and clinicians, and leads to more consistent management approaches.
机译:背景:用于报告甲状腺细胞病理学的Bethesda系统代表了标准化,可重复性,改善的临床意义以及更大的甲状腺细针抽吸物(FNA)预测价值的重要一步。目的:阐明Bethesda系统在报告甲状腺FNA中的实用性。资料与方法:我们回顾性研究了2009年4月至2012年3月之间的甲状腺FNA,使用Bethesda系统对其进行分类,找出了各个Bethesda类别的病例分布,并通过随访组织病理学计算了每个类别的恶性风险。在1020个FNA中,未诊断的为1.2%,良性的为87.5%,非典型性非典型滤泡性病变(AFLUS),可疑的滤泡性肿瘤(SFN)为4.2%,可疑的为恶性肿瘤(SM)1.4%和4.7%的恶性肿瘤。在最初被解释为不可诊断的69例病例中,有12例在再次抽吸后仍未诊断。在323例病例中,有随访组织病理学检查(HPE)的数据。随访HPE报告的恶性率为0%,良性4.5%,AFLUS 20%,SFN 30.6%,SM 75%和恶性97.8%,但无诊断价值。结论:使用Bethesda系统检查甲状腺FNA可以使诊断更多特异性细胞学诊断。在本研究中,贝塞斯达类别中的病例分布与某些研究有所不同,良性病例数较高,非诊断性病例和AFLUS病例数较低。每个类别的恶性肿瘤风险与其他研究相关性很好。因此,贝塞斯达(Bethesda)系统可实现报告的标准化,改善细胞病理学家和临床医生之间诊断术语的理解,并导致更加一致的管理方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号